/

Sociétés

Vi

Non vérifié

ViiV Healthcare

Ce que nous écrivons

IndustrieIndustrie pharmaceutiqueMédecine - DiversSantéVIH, SIDA et maladies auto-immunes

26 communiqués de presse

Voir tous les communiqués de presse

04/08/2026

ViiV Healthcare Launches “Do It For Future You” Campaign Inspiring People to Prioritize Their Sexual Health and Future

Source

ViiV Healthcare

Émetteur

1.00

0

29/07/2026

Événements

VIH, SIDA et maladies auto-immunes

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

Source

ViiV Healthcare

Émetteur

1.00

0

27/07/2026

Événements

Industrie

VIH, SIDA et maladies auto-immunes

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV

Source

ViiV Healthcare

Émetteur

1.00

0

21/07/2026

Événements

Industrie

Science

VIH, SIDA et maladies auto-immunes

Médecine - Divers

Santé

Industrie pharmaceutique

Santé Publique

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

Source

ViiV Healthcare

Émetteur

1.00

0

01/06/2026

PrEP Wisdom: ViiV Healthcare Launches New Campaign to Support Informed HIV Prevention Choices

Source

ViiV Healthcare

Émetteur

1.00

0

10/04/2026

Industrie

Biotechnologie

Industrie pharmaceutique

VIH, SIDA et maladies auto-immunes

Jeunesse

Santé

Vitrines/Shopping

The Time to Talk about HIV is Now: ViiV Healthcare Launches "Still Here" PSA to Ignite Action Around HIV on National Youth HIV/AIDS Awareness Day

Source

ViiV Healthcare

Émetteur

1.00

0

25/02/2026

Industrie

VIH, SIDA et maladies auto-immunes

Santé

Santé Publique

Médecine - Divers

Science

Industrie pharmaceutique

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

Source

ViiV Healthcare

Émetteur

1.00

0

25/02/2026

Événements

Expos

Industrie

VIH, SIDA et maladies auto-immunes

Santé

Santé Publique

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

Source

ViiV Healthcare

Émetteur

1.00

0

18/02/2026

Science

VIH, SIDA et maladies auto-immunes

Médecine - Divers

Biotechnologie

Santé Publique

Industrie pharmaceutique

Santé

Industrie

ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM

Source

ViiV Healthcare

Émetteur

1.00

0

17/02/2026

Événements

Industrie

Science

Biotechnologie

Industrie pharmaceutique

VIH, SIDA et maladies auto-immunes

Santé

Médecine - Divers

ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026

Source

ViiV Healthcare

Émetteur

1.00

0

Followers

0

Compatibilité

0